Objective：To evaluate the efficacy and safety of combined use of solifenacin and tamsulosin in the treatment of benign prostatic hyperplasia（BPH） accompanied by overactive bladder（OAB）. Methods：Totally 105 cases of clinically diagnosed BPH with－out serious obstruction of urinary tract were selected and were randomly assigned to Ⅰ group（n=50） to receive 0.2 mg of tamsulosin once a day and Ⅱ group（n=55） to be treated with 0.2 mg of tamsulosin once a day plus 5 mg of solifenacin once a day at night，both for 12 weeks. Before and after the treatment，international prostate symptom score（IPSS），quality of life（QOL） score，overactive bladder symptom score（OABSS），maximum urinary flow rate（Qmax），24 h micturition frequency，24 h urinary urgency frequency，24 h uroclep－sia frequency and urinary retention times of patients were recorded and used to do evaluation. Results：After 12 weeks medication，the assessable cases were 97；vales of IPSS，QOL，Qmax and 24 h micturition frequency were improved significantly in both groups（P <0.05）. Besides，OABSS，frequent micturition，urinary frequency and uroclepsia in groupⅡ were respectively better than those in groupⅠ（（4.82±1.15 vs. 9.27±2.10），（3.31±0.18 vs. 6.82±2.15），（8.02±2.15 vs. 10.13±2.07），（0.50±0.13 vs. 2.03±0.87），P<0.05）. No significant difference was found between two groups in Qmax（15.81±2.56 vs. 16.04±3.26，P ＞0.05）. No case of acute uri－nary retention occurred in either group. Incidences of adverse reactions in both groups were 4.3% and 8.0% respectively without sig－nificant differences. Conclusions：Combination therapy with tamsulosin and solifenacin is effective and safe in relieving the symptoms of patients with BPH and OAB and improving patient’s quality of life greatly.